Therapeutic potential of CAMPATH‐1H in skeletal tumours
Identifieur interne : 000A66 ( Istex/Corpus ); précédent : 000A65; suivant : 000A67Therapeutic potential of CAMPATH‐1H in skeletal tumours
Auteurs : Raphaela Fritsche-Guenther ; Andreas Gruetzkau ; Aurelia Noske ; Ingo Melcher ; Klaus-Dieter Schaser ; Peter M. Schlag ; Hans-Udo Kasper ; Veit Krenn ; Christine SersSource :
- Histopathology [ 0309-0167 ] ; 2010-12.
English descriptors
Abstract
Fritsche‐Guenther R, Gruetzkau A, Noske A, Melcher I, Schaser K‐D, Schlag P M, Kasper H‐U, Krenn V & Sers C
(2010) Histopathology57, 851–861
Url:
DOI: 10.1111/j.1365-2559.2010.03722.x
Links to Exploration step
ISTEX:826ADE93566B497ABB2225FA0D9E1C7CD4EFCBECLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Therapeutic potential of CAMPATH‐1H in skeletal tumours</title><author><name sortKey="Fritsche Uenther, Raphaela" sort="Fritsche Uenther, Raphaela" uniqKey="Fritsche Uenther R" first="Raphaela" last="Fritsche-Guenther">Raphaela Fritsche-Guenther</name><affiliation><mods:affiliation>Institute of Pathology</mods:affiliation></affiliation></author><author><name sortKey="Gruetzkau, Andreas" sort="Gruetzkau, Andreas" uniqKey="Gruetzkau A" first="Andreas" last="Gruetzkau">Andreas Gruetzkau</name><affiliation><mods:affiliation>German Rheumatism Research center (DRFZ), Leibnitz Institute, Berlin</mods:affiliation></affiliation></author><author><name sortKey="Noske, Aurelia" sort="Noske, Aurelia" uniqKey="Noske A" first="Aurelia" last="Noske">Aurelia Noske</name><affiliation><mods:affiliation>Institute of Pathology</mods:affiliation></affiliation></author><author><name sortKey="Melcher, Ingo" sort="Melcher, Ingo" uniqKey="Melcher I" first="Ingo" last="Melcher">Ingo Melcher</name><affiliation><mods:affiliation>Center for Musculoskeletal Surgery</mods:affiliation></affiliation></author><author><name sortKey="Schaser, Klaus Ieter" sort="Schaser, Klaus Ieter" uniqKey="Schaser K" first="Klaus-Dieter" last="Schaser">Klaus-Dieter Schaser</name><affiliation><mods:affiliation>Center for Musculoskeletal Surgery</mods:affiliation></affiliation></author><author><name sortKey="Schlag, Peter M" sort="Schlag, Peter M" uniqKey="Schlag P" first="Peter M" last="Schlag">Peter M. Schlag</name><affiliation><mods:affiliation>Robert‐Rössle‐Klinikum, Charitè Universitätsmedizin Berlin, Berlin</mods:affiliation></affiliation></author><author><name sortKey="Kasper, Hans Do" sort="Kasper, Hans Do" uniqKey="Kasper H" first="Hans-Udo" last="Kasper">Hans-Udo Kasper</name><affiliation><mods:affiliation>Institute of Pathology, University of Cologne, Cologne</mods:affiliation></affiliation></author><author><name sortKey="Krenn, Veit" sort="Krenn, Veit" uniqKey="Krenn V" first="Veit" last="Krenn">Veit Krenn</name><affiliation><mods:affiliation>Center for Histology, Cytology and molecular Diagnostic, Wissenschaftspark Trier, Trier, Germany</mods:affiliation></affiliation></author><author><name sortKey="Sers, Christine" sort="Sers, Christine" uniqKey="Sers C" first="Christine" last="Sers">Christine Sers</name><affiliation><mods:affiliation>Institute of Pathology</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:826ADE93566B497ABB2225FA0D9E1C7CD4EFCBEC</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1111/j.1365-2559.2010.03722.x</idno><idno type="url">https://api.istex.fr/document/826ADE93566B497ABB2225FA0D9E1C7CD4EFCBEC/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000A66</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000A66</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Therapeutic potential of CAMPATH‐1H in skeletal tumours</title><author><name sortKey="Fritsche Uenther, Raphaela" sort="Fritsche Uenther, Raphaela" uniqKey="Fritsche Uenther R" first="Raphaela" last="Fritsche-Guenther">Raphaela Fritsche-Guenther</name><affiliation><mods:affiliation>Institute of Pathology</mods:affiliation></affiliation></author><author><name sortKey="Gruetzkau, Andreas" sort="Gruetzkau, Andreas" uniqKey="Gruetzkau A" first="Andreas" last="Gruetzkau">Andreas Gruetzkau</name><affiliation><mods:affiliation>German Rheumatism Research center (DRFZ), Leibnitz Institute, Berlin</mods:affiliation></affiliation></author><author><name sortKey="Noske, Aurelia" sort="Noske, Aurelia" uniqKey="Noske A" first="Aurelia" last="Noske">Aurelia Noske</name><affiliation><mods:affiliation>Institute of Pathology</mods:affiliation></affiliation></author><author><name sortKey="Melcher, Ingo" sort="Melcher, Ingo" uniqKey="Melcher I" first="Ingo" last="Melcher">Ingo Melcher</name><affiliation><mods:affiliation>Center for Musculoskeletal Surgery</mods:affiliation></affiliation></author><author><name sortKey="Schaser, Klaus Ieter" sort="Schaser, Klaus Ieter" uniqKey="Schaser K" first="Klaus-Dieter" last="Schaser">Klaus-Dieter Schaser</name><affiliation><mods:affiliation>Center for Musculoskeletal Surgery</mods:affiliation></affiliation></author><author><name sortKey="Schlag, Peter M" sort="Schlag, Peter M" uniqKey="Schlag P" first="Peter M" last="Schlag">Peter M. Schlag</name><affiliation><mods:affiliation>Robert‐Rössle‐Klinikum, Charitè Universitätsmedizin Berlin, Berlin</mods:affiliation></affiliation></author><author><name sortKey="Kasper, Hans Do" sort="Kasper, Hans Do" uniqKey="Kasper H" first="Hans-Udo" last="Kasper">Hans-Udo Kasper</name><affiliation><mods:affiliation>Institute of Pathology, University of Cologne, Cologne</mods:affiliation></affiliation></author><author><name sortKey="Krenn, Veit" sort="Krenn, Veit" uniqKey="Krenn V" first="Veit" last="Krenn">Veit Krenn</name><affiliation><mods:affiliation>Center for Histology, Cytology and molecular Diagnostic, Wissenschaftspark Trier, Trier, Germany</mods:affiliation></affiliation></author><author><name sortKey="Sers, Christine" sort="Sers, Christine" uniqKey="Sers C" first="Christine" last="Sers">Christine Sers</name><affiliation><mods:affiliation>Institute of Pathology</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Histopathology</title><idno type="ISSN">0309-0167</idno><idno type="eISSN">1365-2559</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2010-12">2010-12</date><biblScope unit="volume">57</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="851">851</biblScope><biblScope unit="page" to="861">861</biblScope></imprint><idno type="ISSN">0309-0167</idno></series><idno type="istex">826ADE93566B497ABB2225FA0D9E1C7CD4EFCBEC</idno><idno type="DOI">10.1111/j.1365-2559.2010.03722.x</idno><idno type="ArticleID">HIS3722</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0309-0167</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>CD52</term><term>complement‐dependent cytotoxicity</term><term>osteosarcoma</term><term>skeletal tumours</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Fritsche‐Guenther R, Gruetzkau A, Noske A, Melcher I, Schaser K‐D, Schlag P M, Kasper H‐U, Krenn V & Sers C
(2010) Histopathology57, 851–861</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Raphaela Fritsche‐Guenther</name><affiliations><json:string>Institute of Pathology</json:string></affiliations></json:item><json:item><name>Andreas Gruetzkau</name><affiliations><json:string>German Rheumatism Research center (DRFZ), Leibnitz Institute, Berlin</json:string></affiliations></json:item><json:item><name>Aurelia Noske</name><affiliations><json:string>Institute of Pathology</json:string></affiliations></json:item><json:item><name>Ingo Melcher</name><affiliations><json:string>Center for Musculoskeletal Surgery</json:string></affiliations></json:item><json:item><name>Klaus‐Dieter Schaser</name><affiliations><json:string>Center for Musculoskeletal Surgery</json:string></affiliations></json:item><json:item><name>Peter M Schlag</name><affiliations><json:string>Robert‐Rössle‐Klinikum, Charitè Universitätsmedizin Berlin, Berlin</json:string></affiliations></json:item><json:item><name>Hans‐Udo Kasper</name><affiliations><json:string>Institute of Pathology, University of Cologne, Cologne</json:string></affiliations></json:item><json:item><name>Veit Krenn</name><affiliations><json:string>Center for Histology, Cytology and molecular Diagnostic, Wissenschaftspark Trier, Trier, Germany</json:string></affiliations></json:item><json:item><name>Christine Sers</name><affiliations><json:string>Institute of Pathology</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>CD52</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>complement‐dependent cytotoxicity</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>osteosarcoma</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>skeletal tumours</value></json:item></subject><articleId><json:string>HIS3722</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><qualityIndicators><score>4.308</score><pdfVersion>1.3</pdfVersion><pdfPageSize>595.276 x 782.362 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>140</abstractCharCount><pdfWordCount>4044</pdfWordCount><pdfCharCount>28110</pdfCharCount><pdfPageCount>11</pdfPageCount><abstractWordCount>22</abstractWordCount></qualityIndicators><title>Therapeutic potential of CAMPATH‐1H in skeletal tumours</title><refBibs><json:item><author><json:item><name>G Hale</name></json:item><json:item><name>M Xia</name></json:item><json:item><name>H Tighe</name></json:item><json:item><name>M Dyer</name></json:item><json:item><name>H Waldmann</name></json:item></author><host><volume>35</volume><pages><last>127</last><first>118</first></pages><author></author><title>Tissue Antigens</title></host><title>The CAMPATH‐1 antigen (CDw52)</title></json:item><json:item><author><json:item><name>J Elsner</name></json:item><json:item><name>R Hochstetter</name></json:item><json:item><name>K Spiekermann</name></json:item><json:item><name>A Kapp</name></json:item></author><host><volume>88</volume><pages><last>4693</last><first>4684</first></pages><author></author><title>Blood</title></host><title>Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils</title></json:item><json:item><author><json:item><name>C Kirchhoff</name></json:item></author><host><volume>2</volume><pages><last>17</last><first>9</first></pages><author></author><title>Mol. Hum. Reprod.</title></host><title>CD52 is the ‘major maturation‐associated’ sperm membrane antigen</title></json:item><json:item><author><json:item><name>S Schroter</name></json:item><json:item><name>P Derr</name></json:item><json:item><name>HS Conradt</name></json:item><json:item><name>M Nimtz</name></json:item><json:item><name>G Hale</name></json:item><json:item><name>C Kirchhoff</name></json:item></author><host><volume>274</volume><pages><last>29873</last><first>29862</first></pages><author></author><title>J. Biol. Chem.</title></host><title>Male‐specific modification of human CD52</title></json:item><json:item><author><json:item><name>C Bindon</name></json:item><json:item><name>G Hale</name></json:item><json:item><name>H Waldmann</name></json:item></author><host><volume>18</volume><pages><last>1514</last><first>1507</first></pages><author></author><title>Eur. J. Immunol.</title></host><title>Importance of antigen specificity for complement‐mediated lysis by monoclonal antibodies</title></json:item><json:item><author><json:item><name>W Heit</name></json:item><json:item><name>D Bunjes</name></json:item><json:item><name>M Wiesneth</name></json:item></author><host><volume>64</volume><pages><last>486</last><first>479</first></pages><author></author><title>Br. J. Haematol.</title></host><title>Ex vivo T‐cell depletion with the monoclonal antibody Campath‐1 plus human complement effectively prevents acute graft‐versus‐host disease in allogeneic bone marrow transplantation</title></json:item><json:item><author><json:item><name>MQ Xia</name></json:item><json:item><name>G Hale</name></json:item><json:item><name>H Waldmann</name></json:item></author><host><volume>30</volume><pages><last>1096</last><first>1089</first></pages><author></author><title>Mol. Immunol.</title></host><title>Efficient complement‐mediated lysis of cells containing the CAMPATH‐1 (CDw52) antigen</title></json:item><json:item><author><json:item><name>M Stanglmaier</name></json:item><json:item><name>S Reis</name></json:item><json:item><name>M Hallek</name></json:item></author><host><volume>83</volume><pages><last>645</last><first>634</first></pages><author></author><title>Ann. Hematol.</title></host><title>Rituximab and alemtuzumab induce a nonclassic, caspase‐independent apoptotic pathway in B‐lymphoid cell lines and in chronic lymphocytic leukemia cells</title></json:item><json:item><author><json:item><name>H Waldmann</name></json:item><json:item><name>A Polliak</name></json:item><json:item><name>G Hale</name></json:item></author><host><volume>2</volume><pages><last>486</last><first>483</first></pages><author></author><title>Lancet</title></host><title>Elimination of graft‐versus‐host disease by in‐vitro depletion of alloreactive lymphocytes with a monoclonal rat anti‐human lymphocyte antibody (CAMPATH‐1)</title></json:item><json:item><author><json:item><name>S Giralt</name></json:item></author><host><volume>33</volume><pages><last>43</last><first>36</first></pages><author></author><title>Semin. Oncol.</title></host><title>The role of alemtuzumab in nonmyeloablative hematopoietic transplantation</title></json:item><json:item><author><json:item><name>JF Magliocca</name></json:item><json:item><name>SJ Knechtle</name></json:item></author><host><volume>19</volume><pages><last>714</last><first>705</first></pages><author></author><title>Transpl. Int.</title></host><title>The evolving role of alemtuzumab (Campath‐1H) for immunosuppressive therapy in organ transplantation</title></json:item><json:item><author><json:item><name>AL Cox</name></json:item><json:item><name>SA Thompson</name></json:item><json:item><name>JL Jones</name></json:item></author><host><volume>35</volume><pages><last>3342</last><first>3332</first></pages><author></author><title>Eur. J. Immunol.</title></host><title>Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis</title></json:item><json:item><author><json:item><name>CM Lockwood</name></json:item><json:item><name>G Hale</name></json:item><json:item><name>H Waldman</name></json:item><json:item><name>DR Jayne</name></json:item></author><host><volume>42</volume><pages><last>1544</last><first>1539</first></pages><author></author><title>Rheumatology (Oxford)</title></host><title>Remission induction in Behcet’s disease following lymphocyte depletion by the anti‐CD52 antibody CAMPATH 1‐H</title></json:item><json:item><author><json:item><name>CE Dearden</name></json:item></author><host><volume>6</volume><pages><last>448</last><first>435</first></pages><author></author><title>Rev. Clin. Exp. Hematol</title></host><title>Alemtuzumab in lymphoproliferate disorders</title></json:item><json:item><author><json:item><name>R Guenther</name></json:item><json:item><name>V Krenn</name></json:item><json:item><name>L Morawietz</name></json:item></author><host><volume>201</volume><pages><last>663</last><first>649</first></pages><author></author><title>Pathol. Res. Pract.</title></host><title>Giant cell tumours of the bone: molecular profiling and expression analysis of Ephrin A1 receptor, Claudin 7, CD52, FGFR3 and AMFR</title></json:item><json:item><author><json:item><name>W Remmele</name></json:item><json:item><name>H Stegner</name></json:item></author><host><volume>8</volume><pages><last>140</last><first>138</first></pages><author></author><title>Pathologe</title></host><title>Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER‐ICA) in breast cancer tissue</title></json:item><json:item><author><json:item><name>P Rebello</name></json:item><json:item><name>G Hale</name></json:item></author><host><volume>260</volume><pages><last>302</last><first>285</first></pages><author></author><title>J. Immunol. Methods</title></host><title>Pharmacokinetics of CAMPATH‐1H: assay development and validation</title></json:item><json:item><author><json:item><name>A Osterborg</name></json:item><json:item><name>AS Fassas</name></json:item><json:item><name>A Anagnostopoulos</name></json:item><json:item><name>MJ Dyer</name></json:item><json:item><name>D Catovsky</name></json:item><json:item><name>H Mellstedt</name></json:item></author><host><volume>93</volume><pages><last>153</last><first>151</first></pages><author></author><title>Br. J. Haematol.</title></host><title>Humanized CD52 monoclonal antibody Campath‐1H as first‐line treatment in chronic lymphocytic leukaemia</title></json:item><json:item><author><json:item><name>M Albitar</name></json:item><json:item><name>KA Do</name></json:item><json:item><name>MM Johnson</name></json:item></author><host><volume>101</volume><pages><last>1008</last><first>999</first></pages><author></author><title>Cancer</title></host><title>Free circulating soluble CD52 as a tumour marker in chronic lymphocytic leukemia and its implication in therapy with anti‐CD52 antibodies</title></json:item><json:item><author><json:item><name>EP Cortes</name></json:item><json:item><name>TM Chu</name></json:item><json:item><name>JJ Wang</name></json:item><json:item><name>D Holyoke</name></json:item><json:item><name>HJ Wallace</name></json:item><json:item><name>GP Murphy</name></json:item></author><host><volume>9</volume><pages><last>265</last><first>257</first></pages><author></author><title>J. Surg. Oncol.</title></host><title>Carcinoembryonic antigen in osteosarcoma</title></json:item><json:item><author><json:item><name>FJ Giles</name></json:item><json:item><name>JM Vose</name></json:item><json:item><name>KA Do</name></json:item></author><host><volume>123</volume><pages><last>857</last><first>850</first></pages><author></author><title>Br. J. Haematol.</title></host><title>Circulating CD20 and CD52 in patients with non‐Hodgkin’s lymphoma or Hodgkin’s disease</title></json:item></refBibs><genre><json:string>article</json:string></genre><host><volume>57</volume><publisherId><json:string>HIS</json:string></publisherId><pages><total>11</total><last>861</last><first>851</first></pages><issn><json:string>0309-0167</json:string></issn><issue>6</issue><genre><json:string>journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1365-2559</json:string></eissn><title>Histopathology</title><doi><json:string>10.1111/(ISSN)1365-2559</json:string></doi></host><categories><wos><json:string>science</json:string><json:string>pathology</json:string><json:string>cell biology</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>pathology</json:string></scienceMetrix></categories><publicationDate>2010</publicationDate><copyrightDate>2010</copyrightDate><doi><json:string>10.1111/j.1365-2559.2010.03722.x</json:string></doi><id>826ADE93566B497ABB2225FA0D9E1C7CD4EFCBEC</id><score>0.3620982</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/826ADE93566B497ABB2225FA0D9E1C7CD4EFCBEC/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/826ADE93566B497ABB2225FA0D9E1C7CD4EFCBEC/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/826ADE93566B497ABB2225FA0D9E1C7CD4EFCBEC/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Therapeutic potential of CAMPATH‐1H in skeletal tumours</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><availability><p>© 2010 Blackwell Publishing Limited</p></availability><date>2010</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Therapeutic potential of CAMPATH‐1H in skeletal tumours</title><author xml:id="author-1"><persName><forename type="first">Raphaela</forename><surname>Fritsche‐Guenther</surname></persName><affiliation>Institute of Pathology</affiliation></author><author xml:id="author-2"><persName><forename type="first">Andreas</forename><surname>Gruetzkau</surname></persName><affiliation>German Rheumatism Research center (DRFZ), Leibnitz Institute, Berlin</affiliation></author><author xml:id="author-3"><persName><forename type="first">Aurelia</forename><surname>Noske</surname></persName><affiliation>Institute of Pathology</affiliation></author><author xml:id="author-4"><persName><forename type="first">Ingo</forename><surname>Melcher</surname></persName><affiliation>Center for Musculoskeletal Surgery</affiliation></author><author xml:id="author-5"><persName><forename type="first">Klaus‐Dieter</forename><surname>Schaser</surname></persName><affiliation>Center for Musculoskeletal Surgery</affiliation></author><author xml:id="author-6"><persName><forename type="first">Peter M</forename><surname>Schlag</surname></persName><affiliation>Robert‐Rössle‐Klinikum, Charitè Universitätsmedizin Berlin, Berlin</affiliation></author><author xml:id="author-7"><persName><forename type="first">Hans‐Udo</forename><surname>Kasper</surname></persName><affiliation>Institute of Pathology, University of Cologne, Cologne</affiliation></author><author xml:id="author-8"><persName><forename type="first">Veit</forename><surname>Krenn</surname></persName><affiliation>Center for Histology, Cytology and molecular Diagnostic, Wissenschaftspark Trier, Trier, Germany</affiliation></author><author xml:id="author-9"><persName><forename type="first">Christine</forename><surname>Sers</surname></persName><affiliation>Institute of Pathology</affiliation></author></analytic><monogr><title level="j">Histopathology</title><idno type="pISSN">0309-0167</idno><idno type="eISSN">1365-2559</idno><idno type="DOI">10.1111/(ISSN)1365-2559</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2010-12"></date><biblScope unit="volume">57</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="851">851</biblScope><biblScope unit="page" to="861">861</biblScope></imprint></monogr><idno type="istex">826ADE93566B497ABB2225FA0D9E1C7CD4EFCBEC</idno><idno type="DOI">10.1111/j.1365-2559.2010.03722.x</idno><idno type="ArticleID">HIS3722</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2010</date></creation><langUsage><language ident="en">en</language></langUsage><abstract><p>Fritsche‐Guenther R, Gruetzkau A, Noske A, Melcher I, Schaser K‐D, Schlag P M, Kasper H‐U, Krenn V & Sers C
(2010) Histopathology57, 851–861</p></abstract><abstract><p>Therapeutic potential of CAMPATH‐1H in skeletal tumours</p></abstract><abstract><p>Aims: CD 52 is a glycosylphosphatidylinositol (GPI)‐anchored glycoprotein that is expressed abundantly on all lymphocytes, monocytes, macrophages, eosinophils and in the male genital tract. To date, the physiological role of CD52 on lymphocytes has not been elucidated. However, an antibody directed to CD52 called CAMPATH‐1H has been shown to be capable of depleting lymphocytes. The aim of this study was to analyse tissue and cell lines of non‐neoplastic bone, cartilage and skeletal tumours for CD52 expression.</p></abstract><abstract><p>Methods and results: The expression of CD52 mRNA and protein both in vivo and in vitro was detected. Malignant tumours showed higher CD52 expression compared to benign tumours, suggesting a role in the development and progression of bone tumours. Interestingly, immunohistochemistry and flow cytometry revealed that CD52 was expressed not only on the surface of tumour cells, but also in the cytoplasm. The results obtained in osteosarcoma cells showed that CAMPATH‐1H leads to a complement‐independent reduction of viable cells.</p></abstract><abstract><p>Conclusion: CD52 is expressed in a variety of bone tumours and the in vitro studies presented herein suggest that CAMPATH‐1H treatment might have therapeutic potential for osteosarcoma patients.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>keywords</head><item><term>CD52</term></item><item><term>complement‐dependent cytotoxicity</term></item><item><term>osteosarcoma</term></item><item><term>skeletal tumours</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2010-12">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/826ADE93566B497ABB2225FA0D9E1C7CD4EFCBEC/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Ltd</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1365-2559</doi><issn type="print">0309-0167</issn><issn type="electronic">1365-2559</issn><idGroup><id type="product" value="HIS"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="HISTOPATHOLOGY">Histopathology</title></titleGroup></publicationMeta><publicationMeta level="part" position="12106"><doi origin="wiley">10.1111/his.2010.57.issue-6</doi><numberingGroup><numbering type="journalVolume" number="57">57</numbering><numbering type="journalIssue" number="6">6</numbering></numberingGroup><coverDate startDate="2010-12">December 2010</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="8" status="forIssue"><doi origin="wiley">10.1111/j.1365-2559.2010.03722.x</doi><idGroup><id type="unit" value="HIS3722"></id></idGroup><countGroup><count type="pageTotal" number="11"></count></countGroup><titleGroup><title type="tocHeading1">Original Articles</title></titleGroup><copyright>© 2010 Blackwell Publishing Limited</copyright><eventGroup><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.4 mode:FullText" date="2010-12-17"></event><event type="firstOnline" date="2010-12-17"></event><event type="publishedOnlineFinalForm" date="2010-12-17"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-27"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-24"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="851">851</numbering><numbering type="pageLast" number="861">861</numbering></numberingGroup><correspondenceTo>Dr R Fritsche, Institute of Pathology, Charitè Universitätsmedizin Berlin, Chariteplatz 1, D‐10117 Berlin, Germany. e‐mail: <email>raphaela.fritsche@charite.de</email></correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:HIS.HIS3722.pdf"></link></linkGroup></publicationMeta><contentMeta><unparsedEditorialHistory>Date of submission 5 August 2009 Accepted for publication 23 March 2010</unparsedEditorialHistory><countGroup><count type="figureTotal" number="5"></count><count type="tableTotal" number="3"></count></countGroup><titleGroup><title type="main">Therapeutic potential of CAMPATH‐1H in skeletal tumours</title><title type="shortAuthors"><i>R Fritsche‐Guenther et al.</i></title><title type="short"><i>CD52 in skeletal tumours</i></title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1"><personName><givenNames>Raphaela</givenNames><familyName>Fritsche‐Guenther</familyName></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#a2"><personName><givenNames>Andreas</givenNames><familyName>Gruetzkau</familyName></personName></creator><creator creatorRole="author" xml:id="cr3" affiliationRef="#a1"><personName><givenNames>Aurelia</givenNames><familyName>Noske</familyName></personName></creator><creator creatorRole="author" xml:id="cr4" affiliationRef="#a3"><personName><givenNames>Ingo</givenNames><familyName>Melcher</familyName></personName></creator><creator creatorRole="author" xml:id="cr5" affiliationRef="#a3"><personName><givenNames>Klaus‐Dieter</givenNames><familyName>Schaser</familyName></personName></creator><creator creatorRole="author" xml:id="cr6" affiliationRef="#a4"><personName><givenNames>Peter M</givenNames><familyName>Schlag</familyName></personName></creator><creator creatorRole="author" xml:id="cr7" affiliationRef="#a5"><personName><givenNames>Hans‐Udo</givenNames><familyName>Kasper</familyName></personName></creator><creator creatorRole="author" xml:id="cr8" affiliationRef="#a6"><personName><givenNames>Veit</givenNames><familyName>Krenn</familyName></personName></creator><creator creatorRole="author" xml:id="cr9" affiliationRef="#a1"><personName><givenNames>Christine</givenNames><familyName>Sers</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a1"><unparsedAffiliation>Institute of Pathology</unparsedAffiliation></affiliation><affiliation xml:id="a2"><unparsedAffiliation>German Rheumatism Research center (DRFZ), Leibnitz Institute, Berlin</unparsedAffiliation></affiliation><affiliation xml:id="a3"><unparsedAffiliation>Center for Musculoskeletal Surgery</unparsedAffiliation></affiliation><affiliation xml:id="a4"><unparsedAffiliation>Robert‐Rössle‐Klinikum, Charitè Universitätsmedizin Berlin, Berlin</unparsedAffiliation></affiliation><affiliation xml:id="a5"><unparsedAffiliation>Institute of Pathology, University of Cologne, Cologne</unparsedAffiliation></affiliation><affiliation xml:id="a6" countryCode="DE"><unparsedAffiliation>Center for Histology, Cytology and molecular Diagnostic, Wissenschaftspark Trier, Trier, Germany</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">CD52</keyword><keyword xml:id="k2">complement‐dependent cytotoxicity</keyword><keyword xml:id="k3">osteosarcoma</keyword><keyword xml:id="k4">skeletal tumours</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><p>Fritsche‐Guenther R, Gruetzkau A, Noske A, Melcher I, Schaser K‐D, Schlag P M, Kasper H‐U, Krenn V & Sers C
(2010) <i>Histopathology</i><b>57,</b> 851–861</p><p> <b>Therapeutic potential of CAMPATH‐1H in skeletal tumours</b> </p><p><b>Aims: </b> CD 52 is a glycosylphosphatidylinositol (GPI)‐anchored glycoprotein that is expressed abundantly on all lymphocytes, monocytes, macrophages, eosinophils and in the male genital tract. To date, the physiological role of CD52 on lymphocytes has not been elucidated. However, an antibody directed to CD52 called CAMPATH‐1H has been shown to be capable of depleting lymphocytes. The aim of this study was to analyse tissue and cell lines of non‐neoplastic bone, cartilage and skeletal tumours for CD52 expression.</p><p><b>Methods and results: </b> The expression of CD52 mRNA and protein both <i>in vivo</i> and <i>in vitro</i> was detected. Malignant tumours showed higher CD52 expression compared to benign tumours, suggesting a role in the development and progression of bone tumours. Interestingly, immunohistochemistry and flow cytometry revealed that CD52 was expressed not only on the surface of tumour cells, but also in the cytoplasm. The results obtained in osteosarcoma cells showed that CAMPATH‐1H leads to a complement‐independent reduction of viable cells.</p><p><b>Conclusion: </b> CD52 is expressed in a variety of bone tumours and the <i>in vitro</i> studies presented herein suggest that CAMPATH‐1H treatment might have therapeutic potential for osteosarcoma patients.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Therapeutic potential of CAMPATH‐1H in skeletal tumours</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>CD52 in skeletal tumours</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Therapeutic potential of CAMPATH‐1H in skeletal tumours</title></titleInfo><name type="personal"><namePart type="given">Raphaela</namePart><namePart type="family">Fritsche‐Guenther</namePart><affiliation>Institute of Pathology</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Andreas</namePart><namePart type="family">Gruetzkau</namePart><affiliation>German Rheumatism Research center (DRFZ), Leibnitz Institute, Berlin</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Aurelia</namePart><namePart type="family">Noske</namePart><affiliation>Institute of Pathology</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Ingo</namePart><namePart type="family">Melcher</namePart><affiliation>Center for Musculoskeletal Surgery</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Klaus‐Dieter</namePart><namePart type="family">Schaser</namePart><affiliation>Center for Musculoskeletal Surgery</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Peter M</namePart><namePart type="family">Schlag</namePart><affiliation>Robert‐Rössle‐Klinikum, Charitè Universitätsmedizin Berlin, Berlin</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Hans‐Udo</namePart><namePart type="family">Kasper</namePart><affiliation>Institute of Pathology, University of Cologne, Cologne</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Veit</namePart><namePart type="family">Krenn</namePart><affiliation>Center for Histology, Cytology and molecular Diagnostic, Wissenschaftspark Trier, Trier, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Christine</namePart><namePart type="family">Sers</namePart><affiliation>Institute of Pathology</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">2010-12</dateIssued><edition>Date of submission 5 August 2009 Accepted for publication 23 March 2010</edition><copyrightDate encoding="w3cdtf">2010</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">5</extent><extent unit="tables">3</extent></physicalDescription><abstract>Fritsche‐Guenther R, Gruetzkau A, Noske A, Melcher I, Schaser K‐D, Schlag P M, Kasper H‐U, Krenn V & Sers C
(2010) Histopathology57, 851–861</abstract><abstract>Therapeutic potential of CAMPATH‐1H in skeletal tumours</abstract><abstract>Aims: CD 52 is a glycosylphosphatidylinositol (GPI)‐anchored glycoprotein that is expressed abundantly on all lymphocytes, monocytes, macrophages, eosinophils and in the male genital tract. To date, the physiological role of CD52 on lymphocytes has not been elucidated. However, an antibody directed to CD52 called CAMPATH‐1H has been shown to be capable of depleting lymphocytes. The aim of this study was to analyse tissue and cell lines of non‐neoplastic bone, cartilage and skeletal tumours for CD52 expression.</abstract><abstract>Methods and results: The expression of CD52 mRNA and protein both in vivo and in vitro was detected. Malignant tumours showed higher CD52 expression compared to benign tumours, suggesting a role in the development and progression of bone tumours. Interestingly, immunohistochemistry and flow cytometry revealed that CD52 was expressed not only on the surface of tumour cells, but also in the cytoplasm. The results obtained in osteosarcoma cells showed that CAMPATH‐1H leads to a complement‐independent reduction of viable cells.</abstract><abstract>Conclusion: CD52 is expressed in a variety of bone tumours and the in vitro studies presented herein suggest that CAMPATH‐1H treatment might have therapeutic potential for osteosarcoma patients.</abstract><subject lang="en"><genre>keywords</genre><topic>CD52</topic><topic>complement‐dependent cytotoxicity</topic><topic>osteosarcoma</topic><topic>skeletal tumours</topic></subject><relatedItem type="host"><titleInfo><title>Histopathology</title></titleInfo><genre type="journal">journal</genre><identifier type="ISSN">0309-0167</identifier><identifier type="eISSN">1365-2559</identifier><identifier type="DOI">10.1111/(ISSN)1365-2559</identifier><identifier type="PublisherID">HIS</identifier><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>57</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>851</start><end>861</end><total>11</total></extent></part></relatedItem><identifier type="istex">826ADE93566B497ABB2225FA0D9E1C7CD4EFCBEC</identifier><identifier type="DOI">10.1111/j.1365-2559.2010.03722.x</identifier><identifier type="ArticleID">HIS3722</identifier><accessCondition type="use and reproduction" contentType="copyright">© 2010 Blackwell Publishing Limited</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Blackwell Publishing Ltd</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Rhénanie/explor/UnivTrevesV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A66 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000A66 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Rhénanie
|area= UnivTrevesV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:826ADE93566B497ABB2225FA0D9E1C7CD4EFCBEC
|texte= Therapeutic potential of CAMPATH‐1H in skeletal tumours
}}
| This area was generated with Dilib version V0.6.31. |  |